{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:15:52Z","timestamp":1781630152986,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006312","name":"South African Agency for Science and Technology Advancement","doi-asserted-by":"crossref","award":["113138"],"award-info":[{"award-number":["113138"]}],"id":[{"id":"10.13039\/501100006312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Aspirin is widely used to prevent pregnancy related vascular disorders such as preeclampsia (PE), intrauterine growth restriction and maternal disorders. However, the indications for the use of aspirin during pregnancy is currently controversial because the dosage of aspirin used and the sample sizes in various studies differ considerably. Furthermore, women of African ancestry are more likely to have higher rates of PE and more severe cases than those of their Caucasian counterparts. Yet, there are very few studies in this population group. Therefore, the aim of this review will be to determine the effect of low-dose aspirin (LDA) for prevention of PE in women of African ancestry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Analysis:<\/jats:title>\n            <jats:p>This is a protocol for a systematic review and meta-analysis of published studies on the effect of LDA for prevention of PE. Relevant information will be accessed from the following databases; PubMed, Cochrane Central Register of Controlled Trials, Google Scholar, Google, EBSCO Host, and the Web of Science. The studies will be mapped in 2 stages: stage 1 will map studies descriptively by focus and method; stage 2 will involve additional inclusion criteria, quality assessment and data extraction undertaken by 2 reviewers in parallel. Evidence will be synthesized using relevant systematic research tools. Meta-analysis and subgroup analysis will be conducted using RevMan whilst Stata 13 will be used for meta-regressions. We will follow recommendations described in the preferred reporting items for systematic reviews and meta-analyses statement and the Cochrane Handbook for Intervention Reviews.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>The use of LDA as a prophylactic treatment has been considered for the prevention of PE. However, studies evaluating the use of LDA in women of African ancestry are few. Therefore, with the increase in the prevalence of PE in the African population, it is critical to further investigate the use of LDA in pregnant women of African ancestry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>The review and meta-analysis will not require ethical approval and the findings will be published in peer-reviewed journals and presented at local and international conferences. The findings of this review will inform all stakeholders on current and future guidelines on the use of aspirin in pregnancy, especially in populations of African ancestry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Systematic review registration:<\/jats:title>\n            <jats:p>International prospective Register of Systematic Reviews (PROSERO) number: (CRD42020213213).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027916","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:12:19Z","timestamp":1638537139000},"page":"e27916","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Aspirin in the prevention of preeclampsia"],"prefix":"10.1097","volume":"100","author":[{"given":"P.Z.","family":"Mkhize","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-4528","authenticated-orcid":false,"given":"W.N.","family":"Phoswa","sequence":"additional","affiliation":[{"name":"Department of Life and Consumer Sciences, University of South Africa (UNISA), Science Campus, Florida, Roodepoort, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.P.","family":"Khaliq","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dorsamy","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Medical Sciences College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moodley","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12978-019-0707-8","article-title":"Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study","volume":"16","author":"Vestering","year":"2019","journal-title":"Reprod Health"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"Rana","year":"2019","journal-title":"Circ Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bcpt.13308","article-title":"Aspirin for the prevention and treatment of pre-eclampsia: a matter of COX-1\u200aand\/or COX-2 inhibition?","volume":"127","author":"Mirabito Colafella","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/HYPERTENSIONAHA.118.11196","article-title":"Aspirin effect on adverse pregnancy outcomes associated with stage 1 hypertension in a high-risk cohort","volume":"72","author":"Hauspurg","year":"2018","journal-title":"Hypertension"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"121.e2","DOI":"10.1016\/j.ajog.2016.10.016","article-title":"Antiplatelet therapy before or after 16 weeks\u2019 gestation for preventing preeclampsia: an individual participant data meta-analysis","volume":"216","author":"Meher","year":"2017","journal-title":"Am J Obstetr Gynecol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"287.e1","DOI":"10.1016\/j.ajog.2017.11.561","article-title":"Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M14-1884","article-title":"Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: US Preventive Services Task Force recommendation statement","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann Intern Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/nu7031744","article-title":"Micronutrients in pregnancy in low-and middle-income countries","volume":"7","author":"Darnton-Hill","year":"2015","journal-title":"Nutrients"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jch.13514","article-title":"The burden of hypertensive disorders of pregnancy in Africa: a systematic review and meta-analysis","volume":"21","author":"Noubiap","year":"2019","journal-title":"J Clin Hypertens"},{"key":"R13-20250504","first-page":"4361","article-title":"Low-dose aspirin at\u2264 16\u200aweeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: a systematic review and meta-analysis","volume":"15","author":"Cui","year":"2018","journal-title":"Exp Ther Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2675101","DOI":"10.1155\/2019\/2675101","article-title":"Evidence-based prevention of preeclampsia: commonly asked questions in clinical practice","volume":"2019","author":"Wertaschnigg","year":"2019","journal-title":"J Pregnancy"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/1471-0528.13914","article-title":"Low dose aspirin and pregnancy: how important is aspirin resistance?","volume":"123","author":"Navaratnam","year":"2016","journal-title":"BJOG"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1370\/afm.141","article-title":"What is an intracluster correlation coefficient? Crucial concepts for primary care researchers","volume":"2","author":"Killip","year":"2004","journal-title":"Ann Fam Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/pd.4403","article-title":"Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation","volume":"34","author":"Bujold","year":"2014","journal-title":"Prenat Diagn"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e011801","DOI":"10.1136\/bmjopen-2016-011801","article-title":"Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)","volume":"6","author":"O\u2019Gorman","year":"2016","journal-title":"BMJ Open"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1590\/1414-431X20143629","article-title":"Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial","volume":"47","author":"Souza","year":"2014","journal-title":"Braz J Med Biol Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11906-016-0664-3","article-title":"Aspirin vs heparin for the prevention of preeclampsia","volume":"18","author":"Katsi","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000336662","article-title":"Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis","volume":"31","author":"Roberge","year":"2012","journal-title":"Fetal Diagn Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:37:45Z","timestamp":1746333465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027916"}},"subtitle":["A protocol for systematic review and meta analysis"],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":23,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027916","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"2021-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}